Downregulation of polymeric immunoglobulin receptor and secretory IgA antibodies in eosinophilic upper airway diseases

Hupin, Cloé; Rombaux, Philippe; Bowen, H. J. M.; Gould, Hannah J.; Lecocq, Marylène; Pilette, Charles

doi:10.1111/all.12274

Cited by 29 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…S2‐C). It was also correlated with the number of eosinophils ( r = 0.5, P = 0.004) assessed in our previous study of the same series of patients (Fig. S2‐A).…”

Section: Resultssupporting

confidence: 63%

Features of mesenchymal transition in the airway epithelium from chronic rhinosinusitis

Hupin

Gohy

Bouzin

et al. 2014

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…S2‐C). It was also correlated with the number of eosinophils ( r = 0.5, P = 0.004) assessed in our previous study of the same series of patients (Fig. S2‐A).…”

Section: Resultssupporting

confidence: 63%

Features of mesenchymal transition in the airway epithelium from chronic rhinosinusitis

Hupin

Gohy

Bouzin

et al. 2014

Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous studies have suggested an involvement of chemokines, Th2 cytokines, and immunoglobin (Ig)A in migration, survival, and activation of eosinophils in CRSwNP . Our group has demonstrated a positive correlation between eosinophilia and mast cell activation in CRSwNP .…”

Section: Introductionsupporting

confidence: 60%

“…Previous studies have suggested an involvement of chemokines, Th2 cytokines, and immunoglobin (Ig)A in migration, survival, and activation of eosinophils in CRSwNP. [9][10][11] Our group has demonstrated a positive correlation between eosinophilia and mast cell activation in CRSwNP. 12 Mast cells can be activated by local IgE and then secrete cytokines, chemokines, and lipid metabolitesand therefore facilitate type 2 responses and eosinophilic inflammation in CRSwNP.…”

Section: Introductionmentioning

confidence: 97%

Increased accumulation of CD30 ligand‐positive mast cells associates with eosinophilic inflammation in nasal polyps

Zhai

Zhang

et al. 2018

The Laryngoscope

View full text Add to dashboard Cite

Objective Activation of mast cells associates with eosinophilic inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP). The disease‐specific mast cell‐triggering mechanisms apart from immunoglobulin E are poorly understood in CRSwNP. CD30L/CD30 are members of the tumor necrosis factor/receptor superfamily and display immune modulatory function on mast cells. The aim of this study was to explore the expression and function of CD30 and CD30L in CRSwNP. Methods The mRNA expression of CD30 and CD30L was analyzed by real‐time polymerase chain reaction. The cellular expression of CD30L was determined by immunofluorescence staining. The soluble CD30 levels in nasal tissues were detected by enzyme‐linked immunosorbent assay. HMC‐1 cells, a human mast cell line, were cultured and stimulated with CD30. Results Compared with control tissues, CD30 mRNA expression levels were increased in eosinophilic polyps, and soluble CD30 protein levels were upregulated in both eosinophilic and noneosinophilic polyps with a greater increase in eosinophilic type. CD30 was expressed by T cells and B cells in nasal polyps. The CD30L mRNA expression levels and the number of CD30L+ cells and CD30L+tryptase+ mast cells were increased in eosinophilic polyps but not in noneosinophilic polyps as compared with control tissues. Mast cells accounted for 60% of CD30L+ cells in eosinophilic polyps. CD30 induced HMC‐1 cells to produce interleukin (IL)‐4 and IL‐13 without degranulation. Mast cells expressed IL‐4 and IL‐13 in eosinophilic polyps. The number of CD30L+tryptase+ mast cells was positively correlated with the number of eosinophils and total inflammatory cells in eosinophilic polyps. Conclusion CD30/CD30L‐mediated mast cell activation may promote the eosinophilic inflammation in CRSwNP. Level of Evidence NA Laryngoscope, 129:E110–E117, 2019

show abstract

“…SC protects IgA from degradation and can have, itself, some anti-microbial properties. Hupin et al studied this pathway by analyzing nasal and ethmoidal biopsies, as well as nasal secretions, of patients with CRSwNP, CRSsNP, allergic rhinitis, and controls [27]. The authors found decreased levels of pIgR, SC, and IgA antibodies to Staphylococcus aureus enterotoxin B in patients with CRSwNP.…”

Section: Screeningmentioning

confidence: 99%

Immune deficiency in chronic rhinosinusitis: screening and treatment

Chiarella

Grammer

2016

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction Chronic rhinosinusitis (CRS) is a prevalent disease with a high annual cost of treatment. Immune deficiencies are more common in individuals with CRS and should be especially considered in those patients who are refractory to medical and surgical therapy. Areas covered We performed a literature search in PubMed of the terms “immunodeficiency” and “sinusitis” or “rhinosinusitis” from 2006 through March 2016. All abstracts were reviewed to determine if they pertained to human disease; relevant articles were evaluated in their entirety and included in this review. Expert commentary CRS is a common disease; in those patients with frequent exacerbations or who are refractory to treatment, an immunodeficiency evaluation should be considered. Treatment includes vaccination, antibiotic therapy, immunoglobulin replacement and surgery.

show abstract

Downregulation of polymeric immunoglobulin receptor and secretory IgA antibodies in eosinophilic upper airway diseases

Cited by 29 publications

References 31 publications

Features of mesenchymal transition in the airway epithelium from chronic rhinosinusitis

Features of mesenchymal transition in the airway epithelium from chronic rhinosinusitis

Increased accumulation of CD30 ligand‐positive mast cells associates with eosinophilic inflammation in nasal polyps

Immune deficiency in chronic rhinosinusitis: screening and treatment

Contact Info

Product

Resources

About